Deep sternal wound infections remain among the most serious complications following cardiac surgery.
Early intervention, effective infection control and preservation of healthy tissue are vital. The SteriPlas provides clinicians with a contact-free, Premium Cold Plasma treatment designed to reduce bacterial burden whilst supporting wound healing, even if the multi-resistant bacteria present are protected within biofilm.
Importantly, these clinical benefits are supported by an extensive and growing body of published evidence. Numerous clinical studies have demonstrated the effectiveness of the SteriPlas in managing complex wounds, reducing bacterial burden and supporting the healing process, providing clinicians with confidence in this innovative therapeutic approach.
The ability to deliver Premium Cold Plasma without physical contact makes the SteriPlas particularly attractive when managing delicate postoperative wounds.
Helping clinicians protect patients after surgery is one of the reasons we continue to invest in advancing Cold Plasma medicine through evidence-based innovation.
